CD8A and neoplasm: In particular, Akk‐derived OMV was selected owing to its known capacity to activate CD8+ T cell responses and to recruit tumor‐killing M1 macrophages.[22] OMVs from wild‐type Akk and CD326BL21 were hybridized into CD326hOMV by mixing CD326BL21‐OMV and Akk‐OMV at a mass ratio of 1:2, followed by emulsification and serial extrusion.